Trump announces trade deal with EU following months of negotiations
PRINCETON, N.J. - Bristol Myers Squibb (NYSE: NYSE:BMY), a global biopharmaceutical company with a market capitalization of $121.43 billion, has declared its latest quarterly dividends. The company’s Board of Directors announced a dividend of sixty-two cents ($0.62) per share on its common stock with a par value of $0.10, representing an attractive 4.16% yield. This dividend is set for payment on May 1, 2025, for shareholders on record as of April 4, 2025. According to InvestingPro, BMY has maintained dividend payments for 55 consecutive years, demonstrating remarkable consistency in shareholder returns.
Furthermore, a quarterly dividend of fifty cents ($0.50) per share has been declared for the company’s $2.00 convertible preferred stock. Stockholders of record by the close of business on May 6, 2025, will be eligible for the dividend due on June 2, 2025.
Bristol Myers Squibb focuses on discovering, developing, and delivering innovative medicines aimed at helping patients overcome serious diseases. The company’s commitment to this mission is reflected in its broad portfolio of treatments and its active engagement in research and development.
The declaration of dividends is a routine part of the company’s financial practices, aimed at providing value to its shareholders. These dividends are a direct reflection of the company’s financial health and its ability to generate profit and cash flow.
This announcement is based on a press release statement from Bristol Myers Squibb and provides shareholders and potential investors with important information regarding the company’s distribution of profits in the form of dividends. As is standard practice, the company will distribute these dividends to eligible shareholders on the specified payment dates.
In other recent news, Bristol Myers Squibb has been active with multiple developments across its product portfolio. The U.S. Food and Drug Administration (FDA) has accepted a supplemental biologics license application from the company for a dual therapy involving Opdivo and Yervoy, targeting metastatic colorectal cancer. This treatment has been granted Breakthrough Therapy Designation and Priority Review status, with a decision expected by June 2025. Additionally, Bristol Myers Squibb reported promising results from the CheckMate -816 study, where Opdivo combined with chemotherapy showed a significant survival benefit for patients with resectable non-small cell lung cancer.
However, the company faced a setback with its Phase 3 RELATIVITY-098 trial, which did not meet its primary endpoint for melanoma treatment. Despite this, Opdualag remains a standard of care for certain melanoma patients. In more positive news, the Phase 2 TRANSCEND FL trial demonstrated that Breyanzi met its primary endpoint in treating marginal zone lymphoma, a type of non-Hodgkin lymphoma. This adds to Breyanzi’s efficacy across five cancer types, reinforcing its role as a leading therapy for B-cell malignancies.
Analyst insights from BTIG suggest that Bristol Myers Squibb, along with other healthcare companies, shows promise within the sector. The company’s recent activities, including FDA reviews and trial results, indicate a strong focus on expanding its therapeutic offerings. These developments highlight Bristol Myers Squibb’s ongoing efforts in advancing cancer treatments and maintaining its position in the healthcare sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.